Literature DB >> 7617187

Inclusion body myositis: explanation for poor response to immunosuppressive therapy.

R J Barohn1, A A Amato, Z Sahenk, J T Kissel, J R Mendell.   

Abstract

We treated eight patients who had inclusion body myositis (IBM) with oral prednisone therapy, and we performed muscle biopsies before and after treatment. We documented the patients' clinical response to therapy and changes in serum CK. Although the serum CK level fell, muscle strength worsened after prednisone treatment. In addition, while inflammation decreased in the muscle biopsy specimens, the number of vacuolated and amyloid-positive fibers increased after oral prednisone therapy. These observations indicate that the inflammatory response in IBM may play a secondary role in the pathogenesis of IBM. The unique findings of intracellular amyloid deposits and rimmed vacuoles distinguishing IBM from other inflammatory myopathies, and recognition that suppression of inflammation has no effect on the clinical course, suggest that IBM may represent a degenerative muscle disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617187     DOI: 10.1212/wnl.45.7.1302

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

Review 2.  Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition.

Authors:  Gerald J D Hengstman; Baziel G M van Engelen
Journal:  BMJ       Date:  2004-12-18

Review 3.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

4.  Inflammatory myopathies.

Authors:  B Jane Distad; Anthony A Amato; Michael D Weiss
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

Review 5.  Update on treatment of inclusion body myositis.

Authors:  Maren Breithaupt; Jens Schmidt
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 6.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 7.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 8.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 9.  [Myositides].

Authors:  A Bornemann; S Heitmann; A Lindner
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

10.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.